METTL3 and acute myeloid leukemia: In 2021, Yankova E et al. reported a highly potent and selective first-in-class catalytic inhibitor of METTL3, STM2457, which inhibited AML development by selectively reducing m6A levels and the expression of bromodomain protein 4 (BRD4) mRNA [78].